Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
11/2001
11/14/2001EP0980250B1 Plant extracts for the treatment of increased bone resorption
11/14/2001EP0975581B1 Solid compositions suitable for oral administration comprising l-carnitine or alkanoyl-l-carnitine choline tartrate
11/14/2001EP0971879B1 Solid compositions suitable for oral administration comprising l-carnitine and alkanoyl-l-carnitine magnesium tartrate
11/14/2001EP0777482B1 Combined preparation for the therapy of immune diseases
11/14/2001EP0763037B1 [a]-ANNELATED PYRROLE DERIVATIVES AND PHARMACEUTICAL USE THEREOF
11/14/2001EP0762883B1 Pyridylbisphosphonates for use as a therapeutical agent
11/14/2001CN1322246A Restin and methods of use thereof
11/14/2001CN1322212A Neuropeptide Y agaonists
11/14/2001CN1322202A Quinazoline derivatives
11/14/2001CN1322193A Unsaturated hydroximic acid derivatives as PARP inhibitors
11/14/2001CN1322137A Use of GLP-1 or analogs in treatment of stroke
11/14/2001CN1322132A Bioflavonoid as blood gloucose level lowering agent
11/14/2001CN1322111A Natural tea for curing men's impotence and method for manufacturing the same
11/14/2001CN1321746A Human insuline recombinant gene, preparation method and application
11/14/2001CN1321638A Method for preparing methylsulfonate trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperid-1-yl)-1-propanol
11/14/2001CN1321513A Medicine and food dual-purpose enriched nutrient for resisting AIDS
11/14/2001CN1321501A Flower of artificially-cultivated evening primrose plant superior to evening primrose oil
11/14/2001CN1074762C Process for preparing chromium L-threonate, its preparing process and application
11/13/2001US6316617 For treating physiological disorders associated with an excess of neuropeptide y, such as feeding disorders and certain cardiovascular diseases, medical diagnosis
11/13/2001US6316503 For therapy of disease states associated with cholesterol metabolism such as atherosclerosis and hypercholesterolemia
11/13/2001US6316502 Administering disulfide derivative of dithiocarbamate compound to bind to iron
11/13/2001US6316496 For therapy of retroviral infection; prophylaxis of replication of retrovirus, therapy of aids (acquired immune deficiency syndrome)
11/13/2001US6316484 Pentafluorobenzenesulfonamides and analogs
11/13/2001US6316482 Benzamide derivatives having a vasopressin antagonistic activity
11/13/2001US6316466 Pyrazole derivatives P-38 MAP kinase inhibitors
11/13/2001US6316464 P38 MAP kinase inhibitors
11/13/2001US6316460 Containing a heptenoic acid derivative and a tribasic phosphate salt as a stabilizer; hmg-coa reductase inhibitor
11/13/2001US6316458 Method of enhancing insulin action
11/13/2001US6316431 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents
11/13/2001US6316408 Methods of use for osetoprotegerin binding protein receptors
11/13/2001US6316259 Antisense inhibition of glycogen synthase kinase 3 alpha expression
11/13/2001US6316203 Methods of screening and preparing a composition using DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
11/13/2001US6316002 Germination activated red Ganoderma lucidum spores and method for producing the same
11/13/2001CA2171728C Triaryl-ethylene derivatives for use in therapy
11/08/2001WO2001084158A1 Use of the g protein coupled receptor gpr3 to identify appetite control agents
11/08/2001WO2001083782A2 Novel proteases
11/08/2001WO2001083775A2 Proteases
11/08/2001WO2001083749A2 Gene and sequence variation associated with sensing carbohydrate compounds and other sweeteners
11/08/2001WO2001083746A2 Regulatory nucleic acid sequences of the abc1 gene
11/08/2001WO2001083713A2 The use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same
11/08/2001WO2001083560A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001WO2001083558A1 Agonists/antagonists of the gpr56 receptor as appetite control agents
11/08/2001WO2001083550A2 Gpr22 modulators as appetite-control agents
11/08/2001WO2001083527A2 Glucagon antagonists
11/08/2001WO2001083525A2 Modified peptides, comprising an fc domain, as therapeutic agents
11/08/2001WO2001083524A2 Rna metabolism proteins
11/08/2001WO2001083511A1 Method of searching for arteriosclerosis inhibitors and shrinkers
11/08/2001WO2001083497A1 Cyclipostins, a method for their production and the use of the same
11/08/2001WO2001083489A1 THIENO[2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS
11/08/2001WO2001083486A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
11/08/2001WO2001083478A2 Hydantoin-containing glucokinase activators
11/08/2001WO2001083465A2 Alkynyl phenyl heteroaromatic glucokinase activators
11/08/2001WO2001083454A1 Benzosuberonylpiperidine compounds as analgesics
11/08/2001WO2001083450A2 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
11/08/2001WO2001083438A2 New gamma selective retinoids
11/08/2001WO2001083434A2 P-(sulfonyl)-aryl and heteroaryls amines
11/08/2001WO2001083427A1 PPARη MODULATORS
11/08/2001WO2001083425A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
11/08/2001WO2001082980A1 A medicinal aerosol formulation
11/08/2001WO2001082953A2 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001WO2001082952A2 USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS
11/08/2001WO2001082950A1 Pernasally absorbable insulin preparations
11/08/2001WO2001082928A1 Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
11/08/2001WO2001082924A1 Phosphate transport inhibitors
11/08/2001WO2001082923A1 Estrogen receptor modulators
11/08/2001WO2001082917A2 Treatment of hypertriglyceridemia and other conditions using lxr modulators
11/08/2001WO2001082916A2 Combination therapeutic compositions and methods of use
11/08/2001WO2001082911A2 TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL
11/08/2001WO2001082897A2 Liposome drug delivery
11/08/2001WO2001082873A2 A medicinal aerosol formulation
11/08/2001WO2001082868A2 A medicinal aerosol formulation
11/08/2001WO2001082867A2 A core formulation
11/08/2001WO2001056567A8 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
11/08/2001WO2001041760A3 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
11/08/2001WO2001040180A3 N-substituted 2-cyanopyrrolidines and their use as antidiabetic agents
11/08/2001WO2001039777A8 Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
11/08/2001WO2001037780A8 Urotensin-ii analogs
11/08/2001WO2001032614A3 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof
11/08/2001WO2001030383A3 Medicament in order to induce tolerance
11/08/2001WO2001029012A3 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
11/08/2001WO2001029011A3 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
11/08/2001WO2000074666A3 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia
11/08/2001US20010039352 Production method of isoxazolidinedione compound
11/08/2001US20010039344 Antidiabetic agents
11/08/2001US20010039297 Compositions and method for improving insulin sensivity and glucose metabolism in individuals with impaired fasting glucose or impaired glucose tolerance
11/08/2001US20010039285 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
11/08/2001US20010039280 Optically active 3-[(2-Piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT 1D receptor selective antagonists
11/08/2001US20010039278 Anorectic and antidiabetic agents
11/08/2001US20010039274 Alpha, beta-integrin inhibitors used in the treatment of multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease
11/08/2001US20010039027 Cyclitol containing carbohydrates from human tissue which regulate lipogenic activity
11/08/2001US20010038852 Comprising active ingredient(s), a formulated mixture of polyvinyl acetate and polyvinylpyrrolidone, water soluble polymers or lipophilic additives, conventional excipients
11/08/2001US20010038831 Super-absorbent hydrogel foams
11/08/2001DE10019755A1 New cyclic carboxylic acids are integrin antagonists, useful for treating inflammatory diseases, autoimmune and immune disorders, e.g. atherosclerosis, asthma and diabetes
11/08/2001CA2408105A1 Novel proteases
11/08/2001CA2407965A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001CA2407956A1 Modified peptides as therapeutic agents
11/08/2001CA2407808A1 Cyclipostins, process for their preparation and use thereof
11/08/2001CA2407799A1 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
11/08/2001CA2407797A1 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001CA2407785A1 Use of .alpha.-msh and epo for preventing or treating ischemic conditions
1 ... 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 ... 1298